Every second counts for stroke patients, as studies show they can lose up to 27 million brain cells per minute. Researchers at The University of Texas Health Science Center at Houston (UTHealth) recently published new findings in Stroke that show patients transported to the hospital by mobile stroke unit (MSU) instead of standard ambulance received a clot-busting procedure an average of 10 minutes faster, which could potentially save up to 270 million neurons per patient.

FDA Approves Sapien 3, CoreValve Evolut TAVR Valves for Low-risk Patients

In one coordinated move, the U.S. Food and Drug Administration (FDA) opened transcatheter aortic valve replacement (TAVR) to low-risk patients with the simultaneous approvals of Edwards Lifesciences’ Sapien 3 valve and Medtronic’s CoreValve Evolut system for this critical patient population. The low-risk patient population is the final surgical risk category to be approved for TAVR, a minimally invasive alternative to open-heart surgical valve replacement (SAVR), and includes patients who may be younger and more active than higher-risk patients. Both devices are indicated for patients with severe, symptomatic aortic stenosis (AS).

Bardy Diagnostics Inc. announced that HealthTech Arkansas, a healthcare accelerator and investment fund that connects early-stage healthcare companies with disruptive technologies to Arkansas healthcare providers, has selected BardyDx to participate in the organization's 2019 accelerator program. BardyDx was chosen for its advancements in cardiac monitoring by delivering diagnostic accuracy with the Carnation Ambulatory Monitor (CAM), a P-wave centric ambulatory cardiac patch monitor and arrhythmia detection device.

Thin, flexible fibers made of carbon nanotubes have now proven able to bridge damaged heart tissues and deliver the electrical signals needed to keep those hearts beating.

People enrolled in a large clinical hypertension management trial were half as likely to control their blood pressure if they received care at clinics and primary care practices in low-income areas, according to new research in Journal of the American Heart Association.

Ancora Heart Inc. announced the first patient was enrolled in the CorCinch EU study, a European multi-center clinical evaluation of the AccuCinch Ventricular Repair System as a treatment for patients with reduced ejection fraction systolic heart failure (HFrEF).

Concept Medical Inc. (CMI) has been granted "Breakthrough Device Designation" from the U.S. Food and Drug Administration (FDA) for MagicTouch PTA, its sirolimus drug coated balloon (DCB) catheter, for the treatment of peripheral artery disease (PAD) in below-the-knee (BTK) applications.

A simple change in the way health professionals track their patients’ progress has brought improved healing of life-altering open sores caused by chronic venous insufficiency (CVI) , according to a new article in the Journal for Vascular Surgery – Venous and Lymphatic Disorders.

Non-invasive techniques and devices for assessing blood flow and other diagnostic considerations for people with critical limb ischemia are addressed in a new scientific statement from the American Heart Association. The statement is published in the association’s flagship journal Circulation.

Example of an aortic valve CT imaging workup for TAVR valve sizing and assessing access routes. This patient has an aneurysm in the aortic arch. Image from GE Healthcare.

As we usher in a new era for treating patients with aortic stenosis, we have been reflecting on the evolution of the technology used for transcatheter aortic valve replacement (TAVR) and the evolution of our collaborative process as a team over years as a center in the PARTNER 3 clinical trial. Data presented in 2019 showed low-risk patients fared as well or better with TAVR as they did with surgery.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now